Net Cash Provided by (Used in) Operating Activities of Poseida Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Poseida Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities in USD history and change rate from 31 Dec 2019 to 31 Mar 2024.
  • Poseida Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2024 was $15,135,000, a 60% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $92,167,000, a 244% decline from 2022.
  • Poseida Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $26,772,000, a 74% increase from 2021.
  • Poseida Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was $102,543,000, a 9.5% increase from 2020.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

Poseida Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $15,135,000 +$22,870,000 +60% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q1 2023 $38,005,000 +$13,319,000 +26% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q1 2022 $51,324,000 -$12,268,000 -31% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q1 2021 $39,056,000 -$16,171,000 -71% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q1 2020 $22,885,000 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1

Poseida Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $92,167,000 -$65,395,000 -244% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
2022 $26,772,000 +$75,771,000 +74% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $102,543,000 +$10,785,000 +9.5% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $113,328,000 -$48,810,000 -76% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $64,518,000 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.